Refractory Differentiated Thyroid Gland Carcinoma
5 clinical trials · Condition
◉ Watch Refractory Differentiated Thyroid Gland Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (NCT03914300) | National Cancer Institute (NCI) | 2020-02-10 |
| Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer (NCT01208051) | National Cancer Institute (NCI) | 2010-09-09 |
Track Refractory Differentiated Thyroid Gland Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.